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An Abstract of the Thesis by 
Brendan James-Truman Coulter 
 
 
The utility of genes PTEN and FAS as prognostic markers for the identification of early 
and/or aggressive prostatic adenocarcinomas is seemingly validated in the study results we 
obtained using fluorescence in-situ hybridization (FISH) of archived paraffin embedded surgical 
prostate core biopsy samples obtained from two CLIA and CAP licensed anatomical pathology 
labs (Bostwick Laboratories, Uniondale, NV and GoPath Laboratories, Buffalo Grove, IL). From 
early benign subsets of sample cases to aggressive extracapsular invasive tumors, the presence of 
random deletions evolves into clonal populations of co-deletion of both genes at question. We 
identify independent research that demonstrates the ability of these two genes to work together in 
a pathway of rapid cell division and then (or sometimes concomitant) evasion of said neoplastic 
tumor cell lines from innate cell mediated immunity. Sample size limitations limits predictive 
values in our study, however this research adds credence to personal anecdotal observation I have 
made in the past in the capacity of FISH clinical operations and validation management and 
personal “bench work.” Further, since the onset of our research, using a completely different 
modality, scientists have studied the same markers together and reached the similar if not the 
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According to the American Cancer Society there will be 233,000 new cases of prostate 
cancer diagnosed in 2014. Of these, 29,480 will be terminal. ACS reports that for the same year, 
prostate cancer (PC) will be the second most common cause of death from cancer in the United 
States.  
The World health organization’s HDI (Human Development Index) categorizes more and 
less developed regions of the world based on economy, literacy rate, access to health care as well 
as other factors. In addition, they gather data as it relates to the incidences, mortality and the 
projected growth of the various forms of cancer throughout the world. In a recent published report 
by the WHO affiliated International Agency for Research on Cancer (Cancer Research UK, Jan. 
2014), HDI and regional cancer statistics were combined. The results show the unmistakable 
trend of prostate cancer (incidences and deaths) increasing relative to increases in the HDI.   Even 
more disturbing, this same article ranks PC (+3%) at the top of the projected growth percent for 
2030 as well as five other common cancer types (Lung (+1%), Colorectal (+1%), Breast (+2%), 
Cervical (+2%) and Stomach (-2.5%).   In the past several decades, clinical screening tests, 
especially Pap smears, have proven to be effective in preventing low grade squamous 
intraepithelial lesions (LGSIL) from developing into higher grades including cervical squamous 
or adenocarcinoma.   
In a report published by the Journal of Clinical Oncology¹ found that expensive new 




or robotic MIRT’s (minimally invasive radiation therapy) and brachytherapy (seeding) with or 
without radiation therapy increased dramatically between 2002 and 2005. Clearly there is a need 
to try and push the strategy to beat prostate cancer away from exorbitantly priced treatments, to 
more affordable, more beneficial forms of preventive medicine (molecular diagnostics or 
prognostics and the development of pharmaceuticals with the insight molecular pathology and 


















Current prostate screening methods are either unreliable or invasive. In cervical cancer 
cytology based Pap Smears combined with Human Papilloma Virus (HPV) molecular based virus 
identification are both non-invasive, inexpensive and highly reliable (i.e., when Pap test is 
combined with HPV molecular testing). Prostate screening has historically relied on two 
screening modalities. One type uses quantitative analysis of a specific protein obtained from 
blood samples. This protein, the prostate specific antigen (PSA) is detected and quantified using 
traditional clinical chemistry methods. According to the Mayo Clinic website, limitations of the 
PSA assay are PSA-raising factors such as benign hyperplasia, inflamed and infected prostate 
lowering factors like BPH or urinary drugs or chemotherapy agents, inaccurate results, and 
over-diagnosis in that many of the tumors will not progress to detectable symptoms in their 
lifetime.  The second method of screening is based on the surgical removal of a needle core 
biopsy from specific regions of the prostate gland. Following this surgery the specimen is 
processed for histopathological analysis. By its very nature, prostate surveillance is hampered by 
masculine psychological and societal attitudes with regards to the disease.  Historical cultural and 
behavioral problems seem to be an intrinsic limitation of prostate screening partly due to the 
invasive nature of the standard diagnostic assays.  
The evolution in diagnostics of prostate cancer beyond simple stains and counter-stains 
like H&E (Hematoxylin and Eosin respectively) follow a path that is the antithesis of Francis 




follows the detection of specific proteins associated with cancer, to the detection of RNA 
molecules that code for the protein products related to cancer. Now we are finally beginning the 
herculean task of identifying genes and chromosomal aberrations that relate to cancer.  This effort 
begins with a search for larger microscopic features such as chromosome size/number and 
progresses to an examination of nuclear: cytoplasmic ratios and eventually the spatial relationship 
between nuclei, cells and adjoining tissues.  Early stains relied on variations in staining dependent 
upon variations in cell structure and pH. These early differential or counter stains were the first 
step toward focusing on those cellular characteristics deemed most clinically significant.  
The first step away from early types of stains occurred in 1941 by Gomori. In his paper³ 
uses the differential stain chromium hematoxyln-phloxin. He describes a specific staining 
capability that utilizes the basic environment produced by the insulin producing β cells (Islets of 
Langerhans) to differentially stain, both directly and indirectly, for the presence insulin.  This 
ushered in the era of special stains. 
 In reality, any stain that is not an H&E stain is a special stain. The main body of special 
stains lies in immunohistochemical (IHC) staining or immunofluorescent staining. These stains 
can be visualized by traditional bright field microscopy or fluorescence microscopy. The origin of 
this method can be traced back to 19424. According to a paper written to dedicate the 
contributions of Albert H. Coons the author (Karnovsky)5describes the formulation of a rather 
straightforward approach at selecting antibodies that are specific for the antigenic epitope of 
choice (proteins involved in normal or carcinogenic processes), and then labeling by color or 
fluorescent tags for microscopic analysis.  
IHC for prostate includes several stains. Key among them is P63, which is a homolog of 
the P53 tumor suppressor gene (P53 and P63 can used both diagnostically and prognostically). 
P63 is expressed in the basal cell layer of the epithelium and is involved in embryogenesis. 
CK903 and Cytokeratin 34 beta E12 are basil cell specific anti-keratin antibody stains that when 




are positive in PC lesions and positive in benign lesions. In other words, this is a positive dual 
stain that allows for the differential diagnosis of PC vs. benign tumors. Other positive stains 
include low molecular weight cytokeratin, EMA and CEA. Negative stains include CD10, Muc6 
(normal in lipochrome laden seminal vesicle cells), CK7, CK20 and thrombomodulin. High grade 
PC (Gleason 8-10) do not express the proteins these negative stains pick up. In an attempt to 
supplement positive AMACR IHC researches have directed their attention to the Fatty Acid 
Synthetase6. Using microarray or advanced sequencing analysis, studies have shown increases in 
production of FASn RNA molecules as a backdrop, Wu and associates were able to demonstrate 
increased expression of FASn PC glands by IHC. Although FASn expression is used as a positive 
diagnostic marker when up-regulated, we will see that there is a dichotomy to this extraordinary 
gene, and in fact, it may play a key role in the ability of a tumor suppressor (PTEN) to evade the 
patients cell mediated anti-cancer immunological response. We now find ourselves at the 



















“It appears to me a most excellent thing for the physician to cultivate Prognosis; for by 
foreseeing and foretelling, in the presence of the sick, the present, the past, and the future, and 
explaining the omissions which patients have been guilty of, he will be the more readily believed 
to be acquainted with the circumstances of the sick; so that men will have confidence to entrust 
themselves to such a physician” (Hippocrates, The Book of Prognostics 400 B.C.E.)7.  The art 
The Science of prognostication and its implementation as a viable medical objective or tool is not 
new. In CAP Foundation’s (Conference Series Futurescape of Pathology 2008)8 Jennifer Hunt 
MD of the Cleveland Clinic describes the time-line of diagnostics and prognostics as it relates to 
the technology of the day. Where 1500-1800 represented the period of gross examination as a 
way of achieving these goals. The period between1800-1930 was dominated by microscopic 
analysis. Next electron microscopy gave us deeper insight from 1930-1980. IHC followed from 
1980-2000 and has been the standard tool to differentiate (diagnostics) types of tumors, and give 
us deeper insight into the biology of the individual’s cancer (biomarker prognostics). At the turn 
of the millennia, DNA and the emerging disciplines (e.g., FISH, PCR and next-generation 
sequencing) are now growing into their place as the yardstick for detecting cancer, predicting 
outcomes, and hopefully providing opportunities for developing therapeutic strategies to defeat 
the cancer that is specific even for a single individual. 
Arguably the modern age of prognostics started in 1932 with the classification scheme set 




of the rectal cancer. If the cancer is confined to the rectal tissue there is a better prognosis. If 
growth is seen in the extra-rectal tissue, the prognosis is poorer, and even worse predictions of the 
poorest outcomes are seen in patients where the cancer has metastasized to regional and distant 
lymph nodes respectively. For the most part, traditional pathology, and even diagnostics, relies on 
the identification of a normal vs. atypical state or condition. In short, it is the phenotypic or 
genotypic comparison between abnormal and normal. This can be on an organismal, tissue, 
cellular and even molecular level. Prognostics and modern therapeutics however, rely on a much 
deeper understanding of interactions between all of the aforementioned levels. Today’s 
prognostics mostly involve the identification of genetic alterations and the subsequent proteins, 
pathways and extracellular signaling that are directly affected by these alterations. At center stage 
are the genes and proteins classified as oncogenes and tumor suppressor genes. 
The first oncogene or proto-oncogene was discovered in 1970. However, events dating 
back to 1909 lead to this discovery. In a paper describing the “road to discovering” the first proto-
oncogene10 details the first breakthrough as the point when they identified a hen’s tumor cells 
being transplantable to chickens of the same species11. They determined that the transformative 
agent was a non-cellular filterable particle. Later studies showed that the virus often had 
replicative capacity but not transformative (cancer causing) capability and vise-versa. This in turn 
lead to studies that helped implicates the host genome in the transformation process. Finally, with 
the help of more modern molecular biology techniques, the first proto-oncogene c-SRC was 
discovered. Hence, the presence of this gene can be used in the prognostication of sarcoma. 
Oncogenes convey carcinogenic properties by producing proteins that ramp-up cell cycle 
division, whereas tumor suppressor genes code for proteins that in essence keep the cell cycling 
in check. When deleted, tumor suppressor genes can cause cancer or make it significantly more 
aggressive. Arguably two of the most significant tumor suppressor genes discovered were p53 
and PTEN.  PTEN (phosphatase and tensin homolog) or MMAC1 (mutated in multiple advanced 




respectively in 199712. Subsequent studies have helped cobble together a picture of this amazing 
gene’s role in tumor suppression, and embryogenesis and even apoptosis.  In a review article 
published in 2004 by the Medical Science Monitor, Eric C. Chu and Andrzej S. Tarnawski13 
outline the known basic involvement of the PTEN protein in tumor suppression. It starts with the 
molecular structure and its dual enzymatic capacity. In that they have both protein phosphatase 
and lipid phosphatase activity. Like so many other critical proteins, PTEN is involved in a multi-
tiered pathway that affects cell cycling, growth and apoptosis. They describe the protein as having 
two domains and a tail section. The first motif is made up of the N-terminal region which consists 
of the Phosphatase domain. This is purportedly responsible for the tumor second motif is made up 
of the C-terminal region which consists of the C2 domain and the tail or PDZ domain. The C2 
domain is responsible for PTEN’s affinity for phospholipids. This allows for PTEN to be placed 
appropriately for a signal transduction cascade that involves many proteins. The tail domain 
contains protein kinase CK2 phosphorylation sites which allow for stability and activity of the 
protein. The general pathway starts with PTEN positioning itself on the membrane proximal to a 
tyrosine kinase receptor which as yet is not fully understood, The other major well documented 
area of clinicopathological and molecular diagnostics and prognosis are the and ETS (MAINILY 
TEMPRSS-ERG) fusion related family destruction. 
Prostate cancer displays a “multifocal” pattern when observed in traditional morphologic 
histopathogical analysis, whereby this cancer (PcA) has demonstrated upwards of 79% multifocal 
distribution in one large study by Yoshimoto14 which included 142 prostatectomy specimens all 
positive for PCA. Further, this multifocal characteristic is accompanied by varying genetic 
heterogeneity. As mentioned above, the two major genetic alterations are the ETS genomic 
rearrangements and PTEN loss. According to this study, albeit commonly seen together, PTEN 
loss has a stronger correlation with higher Gleason score than ETS by itself 15. It has therefore 
been determined that PTEN loss demonstrates the ability to be a more useful early biomarker for 




as hemizygous or homozygous. As they point out, however, the ETS rearrangements likely play 
an important role in prostate cancer progression due to the involvement of its promotor region 
driving the expression of the fused ETS gene.  
This is the main crux of this study. Since there is a lack of correlation between ETS 
rearrangements and high Gleason score, could there not be some other “genetic factor” that drives 
the clonal populations towards aggressiveness independent or in combination with a completely 
different mode of clonal expansion and metastatic potential. As we will see, there might be 
something going on with the PTEN loss or more accurately its loss and the concomitant loss of its 



















When trying to determine the clinical outcome of prostate cancers with Gleason scores 
remain the best prognostic markers. With a grant from the Canary Foundation, a multicenter 
retrospective study was performed using tissue microarrays (TMA) to study PTEN. The majority 
of positive core biopsies performed on patients result in a score of 6 or 7. However, upon radical 
prostatectomies performed on the same patients 14-51% and 9% were downgraded (Troyer, 
2015). Another study has shown that clinical stage, which is the second most used indicator does 
not help predict the final stage16. According to the Canary study, of the 55 tumors with 
homozygous deletion 16 had interstitial deletions involving PTEN alone retaining both flanking 
genes in the 4 probe cocktail (fig 5) and 39 homozygous deletions having deletions of all three 
genes (WAPAL, PTEN & FAS). Interestingly, without explanation, they consider the deletion of 
all three genes as mere artifacts. They might be artifacts in as far as their research is concerned 
but their ubiquitous presence in certain clonal populations make it worthy of investigation in 
order to rule out their potential to the overall transformation from indolent to more aggressive 
forms.  Further they report undeleted cases as correlating to Gleason 6 while having a Gleason 
score of 8 was more associated with homozygous deletions. As will be seen, these results are 


















Fatty acid synthase or FAS (also known as APO-1 and CD95) is a gene that codes for the 
FAS ligand and the FAS cell surface receptor which are part of the super family TNF. The 
interaction of this receptor by the FAS ligand has been well documented to induce apoptosis. It 
was first identified by a study done in 1989 by BC Trauth17 in the American Journal of Medicine. 
They were able to induce apoptosis with the use of a monoclonal antibody directed at the FAS 
cell surface receptor. FAS is one of the destruction pathways used by cytotoxic T via MHC class I 
cells to induce apoptosis18. These researchers also note that experimental introduction of DNA 
damage causes a marked upregulation and overexpression of both the FAS ligand and cell surface 
receptor. It is therefore possible for cells undergoing significant genomic stress to upregulate 
these proteins, which in turn find their way to the cell membrane and engage to form a complex 
that ultimately interacts with several intermediate proteins and complexes. These intermediates 
are eventually able activate the protease caspase 8 and finally caspase 3 (fig 7) which cleave 
substrates like the nuclear lamins, actin filaments as well as enzymes responsible for DNA repair. 
DNA fragmentation is often associated with end stage apoptosis. Up regulation and presentation 
of the FAS ligand is known to be associated with cytotoxic T cells thereby making them 
“weaponized.” This affords lymphocytes the ability to interact with and turn on the self-destruct 
triggers in said stressed or compromised cells (e.g., cancer). Interestingly this article points to the 
use of anti-FAS antibody in the treatment of certain diseases such as glumerulonephritis, arthritis 




Over expression of FAS in PCA has been demonstrated in several studies. On the surface, 
no pun intended, the over expression of FAS would seem to rule it out as an early biomarker for 
aggressive type prostate tumors. However, like the presence of FAS mutations in the precursor 
lesions known as PIN (prostatic intraepithelial neoplasia, Bostwick19), and the subsequent lack of 
mutation in the FAS gene in higher grade neoplasia,20 later over expression does not rule out its 
role in the early pathogenesis of aggressive PCA. It is this conundrum, in my opinion, that elicits 
the premature conclusion by the above mentioned Troyer and colleagues use to describe the loss 
of FAS as a mere artifact. 






















Probe were stored at -20°, protected from light. Excess freeze/thaws cycles were avoided. 
Probe were not used beyond their expiration date shown on vial.  All reagents were molecular 
grade. Reagents were labeled, dated, and all prepared reagents were initialed. Parallel test were 
performed on all newly prepared reagents with reagents that have passed manufacturing QC 
requirements. Reagents were prepared and pre-warmed in advance when applicable. Equipment 
was routinely calibrated according to CLIA standards. Control slides were run concurrently with 
patient slides to monitor their assay performance and to assess their accuracy of signal 
enumeration. Control slides were used beginning with the de-paraffinization process onward. 
Reagents were required to reach their desired temperatures prior to initiating the procedure. DNA 
probe were validated with established cut off values. Each hybridized slide was evaluated against 
quality parameters determined by the laboratory. FISH assay results were considered not to be 
informative if the specimen quality and/or specimen slide preparation was inadequate. A rigorous 
quality check was performed before scoring. 
Preparations required before starting procedure 
2ul specimen sections were baked for 3 hours to overnight at 56° C. All reagents and 
stock solutions were prepared prior to the start of teach procedure. Care was taken to make sure 
slides were labeled correctly: probe ID, date, and study number. If an H & E slide corresponding 




areas were marked on the test slide with a diamond tipped pencil on the backside of specimen 
slides(s) prior to processing. Focus on these areas was given when analysis was being performed. 
Equipment 
Fluorescent microscope equipped with recommended filters: DAPI, Aqua, Orange, 
Green, and Red Phase contrast light microscope, Fume hood, Micro-pipettor (1-20 µl), 20-200 
µl), 100-1000 µl), Timer, Magnetic stirrer, Vortex mixer, Microcentrifuge, Water baths, 
Thermobrite or hybrite, pH meter, Hot air oven (56°C), Leica Ariol scanning System 
 Materials 
Calibrated thermometers, Micro test tube racks, Rubber cement, 2 microns section of 
positively charged or,silicanized microscope slides, Glass coverslipps-22x22mm or 24x50 mm, 
Polypropylene micro centrifuged tubes, (1.5ml), Graduated cylinders, Forceps, Coplin jars note: 
gradually heat glass Coplin jars up to 72-80°C otherwise they will crack, Anhydrous Ethyl 
Alcohol. Store at room temperature. Open in fume hood 20x SSC, NP40 or Igepal. Store in dark 
2-8°C, DAPI II store at -20°C, Micropipettor tips 10, 200, 1000, Stir bars, HCl 1.0N soln, 12 N 
HCl, NaOH 1.0N soln, Pepsin Powder, Laboratory wipes, Pyrex bottles -250-500ml, 1L, 1L 
volumetric flasks, DAPI II counterstain (Vysis), Triton X, EDTA, NaBH4, DiH2O, 10% Neutral 
Buffered Formalin (NBF)  
Reagents Preparation  
1X PBS (pH7.2-7.4) 
100mL 10X PBS + 900ml Deionized water 
1% Formaldehyde: 
125 ml of 10% NBF 
370 ml of 1X PBS 
5 ml of 100X MgCl2.  
Store at 2-8°C. 




350 ml Formamide, 50 ml 20X SSC, and 100 ml DI water.  
Store at 2-8°C.  
1mM EDTA  
20X SSC (using 20X SSC powder) 
264g 20XSSC + 900ml of DiH2O. Mix thoroughly. 
Adjust pH to 7.0 and adjust volume to 1L with additional water. Store at 2-8° for 6 months. 
20X SSC  
Dissolve the following in 800ml of DiH20: 
175.3g NaCl and 88.2g NaCitrate 
Adjust the pH to 7.0 with a few drops of 1N HCl or 1N NaOH and adjust the volume to 1L with  




pH to 7.0-7.5.  Store at 4-8°C. 
Wash Solution (0.2XSSC/0.3%NP-40) (1 Liter) 
10mL 20X SSC 
3mL NP40 
Bring up to 1 liter with DiH2O. 
pH to 7.0-7.5.  Store at RT. 
 0.01N HCl (pH 2-2.5) 
 833µL of 12N HCl into 1L DiH2O 
Pepsin 
Stock Pepsin: 10g pepsin to 100ml of purified water 
Aliquot into ~7mL tubes, freeze, expires in 3 months. 





Stock Triton Solution:  
25ml of 2M MgCl2  
125ml of 10X PBs 
850ml of DiH2O 
Working Triton Solution: 
500mL stock triton solution 
2.5mL Triton X 
NaBH4 
Use 1mg of NaBH4 per one milliliter of 1XPBS 
Probe 
3-5µL of Cymogen DX (Irvine, CA) PTEN Del-Tect™ Four Color Probe 
Procedure 
Specimens were cut to 2µm sections from blocks; slides were baked in oven at 56°C for 3 
hours or overnight. Manual Deparaffinization. Slides were immersed in xylene for 2 minutes x 
5changes in a fume hood. Slides were immersed in 100% EtOH for 2 minutes x 5 changes in 
fume hood. Slides were rinsed in diH2O x 3 changes. Antigen retrieval was performed in with 1 
mM EDTA in pressure cooker for 25 min >125° C. They were then rinsed in deionized water 3-4 
times. Slides were taken out and until they cooled down. Slides were placed in 1mg/ml 
NaBH4/1XPBS solution for 10min, and then repeated in fresh solution for 10min, then rinsed in 
several changes of water. Slides were run on Vysis processor using the standard tissue protocol.  
FISH probes were thawed at RT for 10 minutes, vortexed briefly and microcentrifuged 
for 5-10 seconds. The probe was then warmed so that the viscosity decreased sufficiently to allow 
accurate pipetting. 3-5ul was added, with the appropriate amount of anti-fade reagent, to the 
tissue area on the slide, and placed and appropriate sized coverslip was placed on probe area.  




sealed with rubber cement. Thermobrite was set to 83°C for 5 minutes (the co-denature step) and 
then 37°C for 16-24 hours for hybridization. Moisture strips soaked with dH2O and place in the 
slots in the Thermobrite. Test slides were placed flat in the center position to outside. The lid was 
closed and the program ran.  The Thermobrite was not reopened for 16 hours. Probes were 
refrozen @ -20°C.  0.2 XSSC/0.3% NP40 was warmed (~45min) in a water bath. The 
temperature was double checked for the hot wash solution by inserting a thermometer directly 
into the solution, before and after sample slide were added. The solution had to be at 50° +/- 1°. 
Rubber cement was removed from the slide. Slides were placed in RT 2XSSC for 5 min. and 
agitated to remove the coverslips. If coverslip did not come off, the coverslips were gently moved 
to the edge of the slide and flicked off with the fingernail or forceps. Slides were washed in the 
hot wash mixture for exactly 2 minutes at 50°C, while gently agitating the first 30 seconds. Slides 
were transfered to fresh 2XSSC at RT briefly. Air dry slide in dark drawer. Thaw DAPI II 
counterstain. Vortex and pulse microcentrifuge DAPI II. Add 10-15µl DAPI II to the tissue areas 
on the dry slide. Coverslip slide and refreeze DAPI II. Place slide in a slide tray in the freezer for 
~ 30 min or until ready to analyze. 
Controls 
Control slides had to be run concurrently with patient slides in order to monitor the 
assay’s performance and to assess the accuracy of signal review. One positive control slide had to 
be processed for each specimen processing run, and with each new kit lot.  Included was a 
parallel patient slide (previously tested) every time newly prepared reagents were used. 
Specimen Requirements 
Specimen Type(s) including minimum volume/amount to perform assay: Specimen type 
PTEN/FAS FISH prostate biopsy FFPE slides. Minimum volume/amount: 2µm sections from 
tissue block. Specimen collection stability and handling: Specimens had to be fixed in formalin 
24-48 hours of collection. PTEN/FAS FISH assay was performed within 4 weeks of the slide 




specimen was eliminated if the following conditions /criteria occurred: Section cut from tissue 
block and placed on slide was non-representative of original histological diagnosis. Specimen in 
which the representative tissue was exhausted during the histological diagnostic process. Poor 
hybridization (e.g. week or no signals) resulted in equivocal interpretation. Samples that were not 
received in formalin in the histology lab. Samples that were not embedded in paraffin.  
Principles of Fish Evaluation 
When evaluating the results of FISH, several factors were kept in mind: the architecture 
of the tissue, including local variations in neoplastic cell content, fixation, and tumor cellularity 
within the section; the frequent presence of truncated nuclei; and the complex nature of genetic 
arrangements that were seen in some neoplasms. 
Enumeration guidelines for deletion of locus-specific probe on formalin-fixed paraffin-
embedded (FFPE) tissue was provided.  Typically, areas selected for FISH evaluation were 
marked on a Hematoxylin and Eosin (H & E) stained slide that were directly adjacent to section 
being used for FISH. Areas of the FFPE section selected for enumeration had to pass rigorous 
quality criteria as being suitable for FISH analysis as detailed below. 
Evaluation of Selected Areas (marked with diamond pen on back of slide) 
Hybridized slides were evaluated for the specificity of the hybridization, the probe signal 
intensity and the signal to background noise was determined so the hybridization was optimal for 
the given analyses. Typically, at least 85% of all nuclei in the target area were easily enumerable. 
There was a minimum background or nuclear fluorescent "noise". The FISH signal intensity was 
consistently greater than background intensity in the regions of the slide chosen for analysis. 
Thus, background noise was recognized by their lower intensity of the probe signal and different 
shape.  
The target area was scanned using a low power objective to examine cell distribution. 
FISH analysis was normally focused on areas richest in abnormal cells. Variability most often 




useful to keep a conventionally H&E stained section for reference. Select of several areas was 
chosen on the tissue where the cells were evenly distributed yet at a density that several nuclei 
could be evaluated at 40x objective.  
Areas were avoided where the borders of individual nuclei were not clearly identified 
and/or high cell density caused excessive nuclear overlapping. At the same time the quality of the 
tissue section was reviewed, the FISH signals were assessed by selecting and looking for the 
areas with the brightest, most distinct signals while simultaneously having a low background 
“noise.” This made individual nuclei more distinct and easier to enumerate.  In general nuclei 
were selected that had the same intensity and the DAPI staining was mostly uniform. 
The shape and appearance of the DAPI was compared to the H&E or 
immunohistochemical stained nuclei with a focus on the morphological characteristics of the cells 




                      Figure 1B. Areas of interest marked on the H&E slide by the pathologist. 
 
 




The selection of nuclei to score was a distinct step from the actual enumeration of probe 
signals. In a given field of view, the nuclei were scored and first selected on the basis of the 
criteria listed below.  
Enumeration of the nuclei meeting these criteria were scored in an unbiased fashion.   
DAPI/Morphological Criteria: 
Nuclei had bright and uniform DAPI staining. Within adequate specimens, interphase 
cells were required to be well defined and non-disrupted. (Figure 2A) 
A. Prostate cancer cells were selected on the basis of their large size, well-round nucleus 
that was located near the central focal plane (Figure 2B).  Small nuclei or nuclei that 
were below average size were not selected as they may have had truncation affect due 
to the sectioning process. (Figure 2C) 
B. The slide preparation required that they not be under-treated to the point of 
preventing clear identification of the nuclear borders. Over-treated samples had a 
doughnut-like appearance, with the nuclear contents missing from the center and 
were not enumerated. (Figure 3) 
C. Tumor nuclei could not be covered by a cloudy yellowish layer or obscured by auto-
fluorescent structures. 
D. Nuclei were examined that were well separated from each other (touching or 
overlapping nuclei were avoided). (Figure 2D) 
E. The nucleus had to have a consistent size at extreme focal planes along the z-axis. 
This would ensure that the maximum volume of nucleus was present, minimizing 








ENUMERATION OF SIGNALS 
Having selected the optimal group of nuclei to score in the given field of view, I 
proceeded to enumerate the probe signals in the unbiased manner described above. I scored only 
those cells with red (centromeric) signals. This PTEN deletion probe set probe included four 
probes, each labelled with a different fluorophore. Each probe was enumerated on its own using a 
single narrow band pass filter. Beginning with the first probe color and its appropriate filter (FAS 
and aqua or PTEN and RED), I enumerated the signal in a given cell, and proceeded or toggled to 
the next color/filter. I repeated this until all the probes and colors were enumerated for a given 
cell. The number of signals in the nucleus selected for enumeration were recorded separately on 
the score sheet. Only cells with 2 red (centromeric) signals were enumerated. It was usually 
necessary to focus up and down in the z-axis of the focal plane to accommodate the different 




would appear. I counted paired signals (two smaller signals in very close proximity, with distance 
between them less than the size of one signal) as one signal. Following DNA replication during 
mitosis, some nuclei may present paired signals, two smaller signals in very close proximity. 
These paired signals represent a single chromosome already replicated into sister chromatids. I 
evaluated split or questionable signals by observing at higher magnification. I counted only 
nuclei, in which a definite enumeration could be made, I did not analyze or enumerate 
inconclusive cells. I did not evaluate interphase nuclei with multiple signals located on the 
extreme periphery of the nucleus. I recorded accurately the signal count from each cell. When the 
boundary of visible or interpretable nuclei is reached I skipped to the next field of view and 
continued the scanning process. Moving from left to right (or top to bottom) I continued to scan 
the slide for fields with evaluable nuclei. I repeated this scanning process until the appropriate 
number of nuclei was enumerated (50 or more were enumerated depending upon the prevalence 
of the abnormal cells and the area of interest is analyzed).  
Figure 5:   
 
The PTEN probe consists of four colors:  red, orange, green, and aqua.  The red fluor localizes to 




(PTEN).  The green fluor localizes to the WAPAL gene and is centromeric to PTEN, while the 


















FISH results for this study were performed using the same clinical accuracy results 
obtained in laboratory in which the results for this research project was completed using the ASR 
(analyte specific reagent) validation parameters required by CLIA (Clinical Laboratory 
Improvement Amendments). This included parallel results from Bostwick laboratories in New 
York and Orlando, reproducibility (precision) using 3 positive and 3 negative, two technicians 
over the course of 3 days each having a different “running” of samples, sensitivity and specificity 
using known (known conventional surgical pathology diagnoses) and positive threshold (see 






PRECISION   
TABLE 1. DAY 1, RUN 1, TECHNOLOGIST 1 
 
 
CASE # Hemizygous 
deletion  
(% of cells) 
Homozygous 
deletion  




26 8 Abnormal/ Hemizygous 
2 Val-
0022175 
4 34 Abnormal/ Homozygous 
3 Val-
0026865 
22 2 Abnormal/ Hemizygous 
4 Val-
0018480 
8 4 Normal/ Diploid 
5 Val-
0018585 
0 0 Normal/ Diploid 
6 Val-
0018540 
8 6 Normal/ Diploid 
 
TABLE 2. Day 1, Run 1, Technologist 2 
 
CASE # Hemizygous 
deletion     (% of 
cells) 
Homozygous 





30 6 Abnormal/ Hemizygous 
2 Val-
0022175 
14 36 Abnormal/ Homozygous 
3 Val-
0026865 
22 6 Abnormal/ Hemizygous 
4 Val-
0018480 
12 4 Normal/ Diploid 
5 Val-
0018585 






8 10 Normal/ Diploid 
TABLE 3. Day 2, Run 2, Technologist 1 
 
CASE # Hemizygous 
deletion  
(% of cells) 
Homozygous 
deletion  




26 6 Abnormal / Hemizygous 
2 Val-
0022175 
8 30 Abnormal/ Homozygous 
3 Val-
0026865 
24 10 Abnormal / Hemizygous 
4 Val-
0018480 
8 6 Normal / Diploid 
5 Val-
0018585 
0 0 Normal / Diploid 
6 Val-
0018540 
6 12 Normal / Diploid 
 
TABLE 4. Day 2, Run 2, Technologist 2 
 
CASE # Hemizygous 
deletion  
(% of cells) 
Homozygous 
deletion  




30 4 Abnormal / Hemizygous 
2 Val-
0022175 




22 6 Abnormal / Hemizygous 
4 Val-
0018480 
14 6 Normal / Diploid 
5 Val-
0018585 
4 0 Normal / Diploid 
6 Val-
0018540 




TABLE 5. Day 3, Run 3, Technologist 1 
 
CASE # Hemizygous 
deletion  
(% of cells) 
Homozygous 
deletion  




30 6 Abnormal / Hemizygous 
2 Val-
0022175 




28 2 Abnormal / Hemizygous 
4 Val-
0018480 
14 2 Normal / Diploid 
5 Val-
0018585 
2 2 Normal / Diploid 
6 Val-
0018540 
6 12 Normal / Diploid 
 
 
TABLE 6. Day 3, Run 3, Technologist 2 
 
CASE # Hemizygous 
deletion  
(% of cells) 
Homozygous 
deletion 




32 6 Abnormal / Hemizygous 
2 Val-
0022175 




24 0 Abnormal / Hemizygous 
4 Val-
0018480 
12 4 Normal / Diploid 
5 Val-
0018585 
0 0 Normal / Diploid 
6 Val-
0018540 







Diagnostic Sensitivity = 
  
  [20] 











VAL-0006333 Hemizygous Positive 
VAL-0006616 Negative/Diploid 
VAL-0026059 Hemizygous Positive 
VAL-0010531 Negative/Diploid 
VAL-0026876 Hemizygous Positive 
VAL-0027757 Negative/Diploid 


















 (Gleason 8-9) 
Diagnostic Sensitivity = 
  
  [20] 
[20]+ [8] = 71.42% 
Table 8. 
 
VAL-0029477 Hemizygous Positive 
VAL-0003074 Negative/Diploid 
VAL-0006567 Negative/Diploid 
VAL-0018499 Hemizygous Positive 
VAL-0019274 Negative/Diploid 
VAL-0019573 Hemizygous Positive 
VAL-0026462 Homozygous Positive 
VAL-0026865 Homozygous Positive 
VAL-0026910 Negative/Diploid 
VAL-0028404 Hemizygous Positive 
VAL-0028491 Negative/Diploid 
VAL-0028845 Hemizygous Positive 
VAL-0008210 Negative/Diploid 
VAL-0026340 Hemizygous Positive 
VAL-0027758 Negative/Diploid 
VAL-0027943 Hemizygous Positive 
VAL-0028970 Homozygous Positive 
VAL-0029662 Negative/Diploid 
VAL-0007794 Hemizygous Positive 














 (Benign Subset) 
Diagnostic Specificity = 
  [20] 
[20]+ [0] = 100.0% 
Table 9. 
VAL-0000080 Hemizygous Positive 
VAL-0015564 Negative/Diploid 
VAL-0015574 Negative/Diploid 
VAL-0015577 Hemizygous Positive 
VAL-0015578 Negative/Diploid 
VAL-0015588 Hemizygous Positive 
VAL-0015595 Homozygous Positive 
VAL-0015615 Homozygous Positive 
VAL-0015617 Negative/Diploid 
VAL-0015662 Hemizygous Positive 
VAL-0015636 Negative/Diploid 
VAL-0015656 Hemizygous Positive 
VAL-0015658 Negative/Diploid 
VAL-0015663 Hemizygous Positive 
VAL-0015682 Negative/Diploid 
VAL-0015685 Hemizygous Positive 
VAL-0015687 Homozygous Positive 
VAL-0015825 Negative/Diploid 
VAL-0015568 Hemizygous Positive 



















If we take the premise that FAS plays a role in at least one of the pathways to 
tumorigenesis, what might that look like? Whether it is the byproduct of some inherited genetic 
pattern that predisposes certain cells to transition into the progenitors of FAS deletions, PTEN 
deletions or the combination, or some environmental or epigenetic threshold, we ultimately end 
up with these mutated cells. One could image a stepwise progression where first a FAS gene is 
mutated absent of a concomitant PTEN deletion. This FAS deleted cell would be able to, by way 
of processes referenced above, escape apoptotic self-destruction and thrive, divide with ever more 
degrees of genetic instability until it reaches a critical mass whereby the proximal gene PTEN is 
lost as well. At this point not only has the cell attained the ability to escape cytotoxic T cell 
destruction, it has lost a major built in tumor suppressor stop gap system in the PTEN pathogenies 
model. These cells now no longer have the cell cycle control mechanisms and proliferate 
aggressively, all the while going undetected by our cell mediated immunity. Conversely a larger 
deletion encompassing FAS and PTEN would presumably follow a similar evolution with the 
likelihood of a more rapid progression to the type of aggressive clonal populations seen in 
invasive PCA or reach a stage sandwiched between isolated inter-epithelial neoplasia and outright 
malignancy. This hypothetical transition point would be characterized by the rapid division of 
PTENˉ/FASˉ cells which give way to significant genetic instability and thus harbor the classic 




Although my sample size is limited and obviously affects the overall certainty of the 
study, there seems to be some evidence that this is a feasible explanation in that there is a 
simultaneous presence of clearly malignant prostate tumor cells having either heterozygous or 
hemizygous deletions of FAS and PTEN genes and the presence of massive prostate tumor cells 
with marked increases in chromosomes (polysomic genomes) and amplified genes (see fig.). 
Perhaps the best evidence for the progression of PTENˉ/FASˉ or 10q23.2–10q23.3 is seen in 
figure 7, whereby both a population of single hemizygous PTENˉ/FASˉ and the marked nuclear 
diameter sized nuclei with severe genetic instability or tumorgenecity having increases in 
genomes/genes across the whole genome. 
In a recent study21 using SNP (Single Nucleotide Polymorphism) “Nex-Gen” sequencing, 
Ibeawuchi and colleagues elaborate on a direct connection between simultaneous deletion of both 
the PTEN and FAS gene and their role in aggressive Pca clonal subtypes. Their study included a 
long clinical follow-up period that ranged from 2.0–9.7 (mean 5.4) years. The sample size and the 
longitudinal nature of this research elicits confidence in my original belief that the two deletions 
are more than genomic coincidences.  I believe it is worth noting that this published paper was 
released subsequently to my thesis statement and data collection. Moreover, limitations of 
quantitative experiments, in my opinion, are exposed here. In that, the end product of aggressive 
tumors relating to concomitant deletion of these two genes are clear in both my investigation and 
this published study, however the simi-quanitative nature of FISH microscopy allows for the 
morphological and the associated genomic marker changes which inform a more clear evolution 
of simple single deletion to the devastating simultaneous deletion of both genes—creating the 
dynamic tumor suppressor (PTEN) with inflammatory evading biochemistry (FAS).  
This study strengthens my belief in the utility of real-time nucleic acid or polypeptide 
fluorescence reporter microscopy (e.g., confocal microscopy) or alternatively the step-wise 
“snap-shot” morphological/genomic changes seen in paraffin embedded FISH analysis. Knowing 




one I anecdotally discovered and described in this project. PTEN, like other well researched 
tumor suppressor and oncogenes, plays a role in multiple neoplastic pathways in multiple tumor 
sites with presumably multiple cancer progression rates and clonal subtypes. The question, if 
validated, is there a recurrent or reproducible progression that can be detected to aid in treating 
this pathogenesis or even manipulated in order to prevent this disease out-right. 
 



















This project was born from the observation that the four probe flanking construct that in 
theory would identify truncation (cutting off) artifact of portions of the chromosome of interest 
was not working as intended. That is, instead of there being red (Chromosome 10), green 
(WALPAL) and aqua (FAS) present with the gold or orange (PTEN) deleted in indicative cases, 
we consistently observed the red chromosomal copy control signal alone by itself. From this 
arose many questions. A key question from a clinical accuracy point-of-view was were these the 
result of wide spread massive truncation artifact (i.e. the cutting of the entire complement of 
PTEN, FAS and WALPAL) or something actually occurring in-situ. I think it is abundantly clear 
through the data sets that we have collected, that the pattern of clonal populations that have both 
morphological changes associated with prostatic adenocarcinoma and concurrent single copy 
control signals with the loss of all signals are not a coincidence. If you compare benign subsets to 
the aggressive metastatic subsets, you evolve from sporadic rare events of cells demonstrating 
this single copy control red signal to this condition being the norm and actually demarcating a 
given clonal population. I decided to make this my research after hearing that FAS was a key 
immunological gene. The connection between inflammation and cancer is becoming more 
apparent and my anecdotal work observations seem to fit into this newly found etiological player 
in neogenesis.  The potential connection between these patterns genomically, morphologically or 
the type of cancer progression and the immune escape is exciting because further research and 




to evolve and kill, and ultimately allow us to design better methods of diagnostics, prognostics 
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